NCCN Recommendations for Evaluation and Management of Breast Cysts and Fibrocystic Changes

Simple Breast Cysts

Simple cysts are benign lesions that require no treatment beyond routine age‑appropriate breast screening when clinical examination and ultrasound are concordant. 1
Sonographically, simple cysts appear anechoic with well‑circumscribed, round or oval borders and posterior acoustic enhancement. 1
Therapeutic aspiration is indicated only for patients with persistent symptoms (e.g., pain or discomfort); it is not required for asymptomatic simple cysts. [1][2]
After confirming a simple cyst with concordant clinical and imaging findings, patients resume routine screening protocols. 1

Management options include either aspiration or short‑term surveillance (clinical exam + ultrasound ± mammography) every 6–12 months for 1–2 years. [1][2]
Complicated cysts share most features of simple cysts but may contain low‑level echoes or intracystic debris; they lack solid components, intracystic masses, thick walls, or thick septa. 1
The risk of malignancy in complicated cysts is very low, estimated at < 2 %. 1
Aspiration should be strongly considered for patients at high risk of loss to follow‑up. 1
If aspiration yields clear (blood‑free) fluid and the mass resolves, the patient is monitored with clinical examination; a persistently negative exam allows return to routine screening. 2
Cytologic evaluation of cyst fluid is required only when the aspirated fluid is bloody. 1
Any increase in size of a complicated cyst during surveillance mandates tissue biopsy. [1][2]
Persistence of a mass after aspiration also requires tissue biopsy. 1

Complex cysts carry a 14–23 % risk of malignancy and therefore require tissue biopsy. [1][2]
Sonographically, complex cysts contain both anechoic (cystic) and echogenic (solid) components, including thick walls, thick septa, and/or intracystic masses. 1
Ultrasound‑guided core needle biopsy is the preferred diagnostic method. [1][2]
When biopsy results are benign and imaging is concordant, patients undergo clinical examination ± ultrasound or mammography every 6–12 months for 1–2 years to confirm stability. 2
If the lesion enlarges during surveillance, repeat tissue sampling is indicated. 2
Lesions that remain stable throughout surveillance can return to routine screening. 2

When a biopsy of fibrocystic change reveals atypical hyperplasia, the patient should receive breast‑cancer risk‑reduction therapy in accordance with established risk‑reduction guidelines. 2

Discordance between pathology results and imaging findings must not be accepted; it necessitates repeat sampling or surgical excision. 2
Cytologic examination of cyst fluid should be performed only when the fluid is bloody; otherwise it is unnecessary. [1][2]

The National Comprehensive Cancer Network recommends that breast cysts be managed based on their ultrasound classification into simple, complicated, or complex types, with simple cysts requiring only routine screening, complicated cysts managed with either aspiration or short-term surveillance, and complex cysts mandating tissue biopsy due to their 14-23% malignancy risk 3
Simple cysts are essentially benign and not associated with subsequent breast cancer development, with ultrasound features including anechoic (cystic), well-circumscribed, round or oval with well-defined imperceptible wall and posterior acoustic enhancement, and management involving routine screening only if clinical and imaging findings are concordant 3, 4
Complicated cysts have a very low malignancy risk (<2%), with ultrasound features including most but not all elements of a simple cyst, and management options including aspiration or short-term surveillance with physical examination and ultrasound ± mammography every 6-12 months for 1-2 years 3, 4, 5
Complex cysts have a relatively high malignancy risk (14-23%), with ultrasound features including discrete solid components, and management involving core needle biopsy 3, 4, 5

In cases of bloody fluid on aspiration, the National Comprehensive Cancer Network recommends placing a tissue marker followed by cytologic evaluation of fluid, with percutaneous vacuum-assisted biopsy or surgical excision if cytology is positive, and physical examination ± ultrasound/mammogram every 6-12 months for 1-2 years if cytology is negative 5
For post-biopsy follow-up, the National Comprehensive Cancer Network recommends routine screening or physical examination at 6-12 months ± imaging for 1 year to ensure stability for benign concordant results, with surgical excision required for increasing lesions 3, 4

The National Comprehensive Cancer Network recommends follow-up intervals for complicated cysts of every 6-12 months, with a duration of 1-2 years, and imaging modalities including physical examination and ultrasound ± mammography, with an endpoint of returning to routine screening if stable, or proceeding to biopsy if progression 3, 4, 5